CervoMed Inc. — Director's Dealing 2019

Jul 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2019-06-13

Reporting Person: Giles Mark T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-13	Stock Option (Right to Buy)	$3.15	A	13100	Acquired	2029-06-13	Common Stock (13100)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	294	Indirect
Common Stock	53513	Indirect

Footnotes

F1: The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on June 13, 2019.